• Monomethyl Auristatin E: Targeted Payloads for Cancer Cell P

  2026-05-19

  This thought-leadership article explores the mechanistic underpinnings and translational strategy of Monomethyl auristatin E (MMAE) as a next-generation payload in antibody-drug conjugates (ADCs). It integrates recent epigenetic insights on cancer cell plasticity, experimental validation in xenograft models, and the evolving clinical landscape, while providing actionable guidance for translational researchers. By contextualizing APExBIO’s MMAE (SKU: A3631) within emerging paradigms, the article highlights how innovation in cytotoxic payloads can address poorly differentiated and resistant solid tumors.

• GANT61 Induces Apoptosis in ALK+ ALCL via Hh-PIK3IP1-Akt Axi

  2026-05-19

  This study establishes that GANT61, a direct Hedgehog pathway inhibitor, suppresses cell proliferation and induces apoptosis in ALK-positive anaplastic large cell lymphoma by modulating the Hh-PIK3IP1-Akt signaling axis. The findings provide mechanistic insight into Gli1 inhibition as a targeted therapeutic strategy and underscore the importance of robust apoptosis detection methods in translational lymphoma research.

• Optimizing Angiogenesis Assays with Anlotinib Hydrochloride

  2026-05-18

  This article addresses key experimental challenges in angiogenesis and proliferation assays, demonstrating how Anlotinib hydrochloride (SKU C8688) streamlines workflows and enhances data reliability. Backed by quantitative evidence and preclinical literature, it guides biomedical researchers in leveraging this multi-target tyrosine kinase inhibitor for robust, reproducible results.

• MK-1775 (Wee1 Kinase Inhibitor): Optimizing DNA Damage Respo

  2026-05-18

  MK-1775, a potent Wee1 kinase inhibitor from APExBIO, streamlines cell cycle checkpoint abrogation and robustly sensitizes p53-deficient tumor cells to DNA-damaging agents. This article delivers actionable workflows, experimental insights, and troubleshooting strategies to maximize MK-1775's impact in cancer research.

• LDH Cytotoxicity Assay Kit for Precise Cell Damage Quantific

  2026-05-17

  Unlock streamlined, non-radioactive cell cytotoxicity measurement with the LDH Cytotoxicity Assay Kit from APExBIO. This article details advanced workflows, troubleshooting, and protocol insights for maximizing assay sensitivity in cancer, neurodegeneration, and nanomaterial biocompatibility research.

• Clathrin-Mediated Entry of GCRV: Inhibitor Analysis and Impl

  2026-05-16

  Wang et al. (2018) revealed that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated, pH-dependent endocytosis. Their systematic inhibitor profiling clarified the specific cellular pathways involved in viral entry, providing a framework for future studies on cytoskeletal involvement in viral infection mechanisms.

• Modulating Microglial Senescence in Aged White Matter via Bc

  2026-05-15

  This study demonstrates that senescent and disease-associated microglia accumulate in hippocampus-adjacent white matter during aging, contributing to structural and molecular dysfunction. By targeting Bcl-2 and p16ink4a, the research shows these maladaptive microglial states are modifiable, opening avenues for senotherapeutic interventions in brain aging.

• MitMAB in Organoid Models: Precision Tools for Endocytosis M

  2026-05-15

  Discover how MitMAB, a potent N,N,N-trimethyltetradecan-1-aminium bromide compound, enables unprecedented mechanistic clarity in endocytosis and membrane trafficking assays using organoid models. This article uniquely integrates protocol guidance, advanced assay design, and insight from recent ISC-based vesicle uptake studies.

• Bobcat339: Unlocking TET-Driven Epigenetic Control in Diseas

  2026-05-14

  Discover how Bobcat339, a cytosine structure-based TET enzyme inhibitor, enables deeper exploration of DNA methylation regulation in complex disease models. This article uniquely connects mechanistic insight to practical assay strategy, advancing epigenetics research beyond protocol basics.

• Imeglimin Enhances Mitochondrial Function in CTS SSCT Cells

  2026-05-14

  This study demonstrates that Imeglimin significantly improves mitochondrial function and reduces apoptosis in subsynovial connective tissue (SSCT)-derived cells from patients with idiopathic carpal tunnel syndrome. By utilizing multiparametric assays, the authors provide new evidence supporting mitochondrial dysfunction as a therapeutic target in CTS and establish quantitative frameworks for future research.

• Methyl-β-cyclodextrin: Technical Guidance for Membrane Studi

  2026-05-13

  Methyl-β-cyclodextrin (SKU C6939) is a high-purity reagent designed for selective extraction of cholesterol and other lipids from cellular membranes, enabling precise modulation of membrane fluidity and organization. It is best used in cell-based and biochemical workflows investigating membrane dynamics, lipid raft structure, and cholesterol-dependent signaling. This product is not intended for diagnostic or clinical applications and requires adherence to specific handling and storage protocols to maintain efficacy.

• β-Hydroxybutyrylation of ARG1 Reprograms Arginine Metabolism

  2026-05-13

  This study uncovers how abnormal β-hydroxybutyrylation of arginase-1 (ARG1) drives arginine metabolic reprogramming in colorectal cancer (CRC). By elucidating a novel post-translational modification axis involving ARG1-Kbhb, P300, and SLC3A2, the research clarifies mechanisms linking metabolic shifts to tumor progression and suggests new therapeutic approaches targeting ARG1's enzymatic and non-enzymatic functions.

• Glucocorticoids Promote Steroid Resistance in T-ALL via IL-7

  2026-05-12

  This study uncovers a paradoxical mechanism by which glucocorticoids (GCs), essential for T cell acute lymphoblastic leukemia (T-ALL) therapy, can induce their own resistance through upregulation of the IL-7 receptor and downstream BCL-2 signaling. These findings provide a mechanistic basis for GC resistance in T-ALL and highlight potential intervention points for restoring therapy sensitivity.

• Strategic Use of P2Y11 Antagonists in Cancer and Immunology

  2026-05-12

  This article explores the mechanistic and translational value of NF 340, a highly selective P2Y11 antagonist, in dissecting purinergic GPCR signaling in cancer and immune modulation. Building on the latest empirical evidence, including the reversal of breast cancer invasiveness via P2Y11 inhibition, it delivers practical protocol parameters, strategic insights for translational researchers, and a forward-thinking outlook on the future of GPCR-targeted research tools.

• Bay 11-7821 in Sepsis & Inflammatory Research: Mechanisms an

  2026-05-11

  Explore how Bay 11-7821 (BAY 11-7082) advances inflammatory signaling pathway research, uniquely bridging NF-κB inhibition with emerging insights from lactate-driven macrophage biology. Detailed protocols and critical assay considerations set this article apart.

15074 records 8/1005 page Previous Next First page 上5页 678910 下5页 Last page